mTOR Inhibitor
Showing 1 - 25 of 7,813
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +
Not yet recruiting
- Breast Cancer
- +3 more
- AI+CDK4/6i
- +7 more
-
Miami, FloridaUniversity of Miami
Apr 12, 2023
Bile Acids in Acute Insulin Resistance
Recruiting
- PI3K Gene Mutation
- +4 more
- Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
-
New York, New YorkColumbia University Medical Center
Oct 6, 2022
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)
Recruiting
- Lung Cancer Squamous Cell
- +3 more
-
Boston, Massachusetts
- +2 more
Jan 9, 2023
Pulmonary Hypertension Trial in United States (ABI-009, nab-rapamycin, albumin-bound rapamycin)
Active, not recruiting
- Pulmonary Hypertension
- ABI-009, nab-rapamycin, albumin-bound rapamycin
-
Tucson, Arizona
- +5 more
Aug 22, 2022
Metastatic Breast Cancer Trial in France (Biopsy)
Completed
- Metastatic Breast Cancer
- Biopsy
-
Angers, France
- +11 more
Sep 19, 2022
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)
Active, not recruiting
- Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis 1
-
Washington, District of Columbia
- +4 more
Apr 1, 2022
Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory
Recruiting
- Advanced Malignant Neoplasm
- +3 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Brain and CNS Tumors Trial in Memphis (GDC-0084, radiation therapy)
Completed
- Brain and Central Nervous System Tumors
- GDC-0084
- radiation therapy
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jan 13, 2023
Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or
Recruiting
- Triple-negative Breast Cancer
- Pyrotinib with Capecitabine
- +6 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2022
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer Trial in Buffalo, Rochester
Terminated
- Clear Cell Renal Cell Carcinoma
- +3 more
- panobinostat
- +7 more
-
Buffalo, New York
- +1 more
Aug 11, 2022
Angiofibroma of Face, Tuberous Sclerosis Trial in China, United States (Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment)
Recruiting
- Angiofibroma of Face
- Tuberous Sclerosis
- Sirolimus 0.2%
- +2 more
-
Phoenix, Arizona
- +7 more
Feb 2, 2022
PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)
Completed
- PIK3CA Mutation-Related Tumors
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 9, 2023
Glioblastoma, Adult Trial in United States (Paxalisib (GDC-0084))
Active, not recruiting
- Glioblastoma, Adult
- Paxalisib (GDC-0084)
-
Los Angeles, California
- +5 more
Aug 16, 2022
Acute Lymphoblastic Leukemia Trial in United States (Everolimus, Prednisone, Vincristine)
Completed
- Acute Lymphoblastic Leukemia
- Everolimus
- +5 more
-
San Francisco, California
- +7 more
Aug 5, 2022
Advanced Cancers Trial in Houston (Hydroxychloroquine, Sirolimus, Vorinostat)
Completed
- Advanced Cancers
- Hydroxychloroquine
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 3, 2021
Advanced Cancers Trial in Houston (other, drug, behavioral)
Terminated
- Advanced Cancers
- Placebo
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 4, 2021
Everolimus Related Pneumonitis in MBC
Completed
- Everolimus
- Pneumonitis
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 16, 2020
Breast Cancer Trial in Los Angeles, Bronx (Gedatolisib, Faslodex, Palbociclib)
Active, not recruiting
- Breast Cancer
- Gedatolisib
- +3 more
-
Los Angeles, California
- +1 more
Jan 25, 2022
Advanced or Metastatic Pancreatic Adenocarcinoma Trial in Germany (everolimus)
Completed
- Advanced or Metastatic Pancreatic Adenocarcinoma
-
Halle, Germany
- +4 more
Dec 17, 2020
Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Anakinra, Denosumab,
Completed
- Advanced Malignant Neoplasm
- +3 more
- Anakinra
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 24, 2021
Advanced Cancer, Solid Tumor Trial in Houston (Vemurafenib, Everolimus, Temsirolimus)
Completed
- Advanced Cancer
- Solid Tumor
- Vemurafenib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jun 1, 2020